April 1st 2024
Acceptance of the IND application would initiate a first-in-human phase 1 dose expansion and escalation trial of CTIM-76 in patients with testicular and gynecologic cancers.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Pembro plus axitinib is new standard in advanced RCC
July 8th 2019On the basis of findings from the KEYNOTE-426 study, the combination of pembrolizumab (KEYTRUDA) plus axitinib (Inlyta) represents a new standard as front-line treatment for metastatic clear cell renal cell carcinoma, said Thomas Powles, MD.
Prostate cancer guideline update includes genomically informed therapies
June 20th 2019Integration of tumor genetic testing and genomically-informed therapies into clinical practice for patients with advanced prostate cancer are featured in updated National Comprehensive Cancer Network guidelines on the management of prostate cancer (version 2.2019).
Sense of urgency surrounds BCG shortage
June 12th 2019As urologists maneuver through the third shortage of bacillus Calmette-Guérin during the past decade, there is a sense of urgency to find short- and long-term alternative treatments to the only FDA-approved BCG strain as a therapeutic agent for nonmuscle-invasive bladder cancer.
The BCG shortage: No short-term solution!
April 25th 2019"Bacillus Calmette-Guerin (BCG) intravesical immunotherapy is the most effective treatment for management of our patients with non-muscle invasive bladder cancer. What do we do without it, and how do we explain the current worldwide BCG shortage to our patients?" writes Adele M. Caruso, DNP, CRNP.
Germline mutations linked to grade reclassification during AS
April 11th 2019Men with prostate cancer who are carriers of germline pathogenic mutations in the DNA repair genes BRCA1/2 and ATM are at increased risk for grade reclassification during active surveillance, according to research reported by H. Ballentine Carter, MD, at the 2018 AUA annual meeting in San Francisco.
Cabozantinib improves mRCC outcomes regardless of PD-L1 status
April 10th 2019Cabozantinib (Cabometyx) demonstrated consistent improvement in progression-free survival and overall survival (OS) over everolimus (Afinitor) and sunitinib (Sutent), irrespective of PD-L1 status, across two randomized controlled clinical trials in patients with metastatic clear cell renal cell carcinoma.
Minimally invasive cystectomy linked with shorter hospital stay
March 25th 2019Compared to an open approach, minimally invasive radical cystectomy was associated with a near 2-day shorter hospital stay in bladder cancer patients treated at diverse institutions across the United States, according to authors of a recent retrospective analysis of Medicare claims.
ADT’s benefit studied in post-RP men undergoing salvage RT
March 10th 2019"Biochemical recurrence after radical prostatectomy may occur in 20% to 50% of cases and salvage radiation therapy is considered the best treatment in most cases. But the questions about whether to add androgen deprivation therapy, as well as its dose and duration, remain subjects of active clinical debate," writes Badar M. Mian, MD.